Voxel Biotech spun out from UNSW's Centre for Quantum Technologies and produces automated bioreactors that generate perfusable tissue constructs at scale. The Sydney team licenses platform access to research labs, CROs, and pharma companies, reducing culture cycles and improving reproducibility. Pilot programs are underway with Garvan Institute and AstraZeneca Australia.